About RNA Diagnostics

This author has not yet filled in any details.
So far RNA Diagnostics has created 61 blog entries.

RDA™ Evolves into Platform Technology

While the primary focus of RNA Disruption Assay (RDA) continues to be breast cancer chemotherapy management, it is rapidly evolving into a platform technology that will be utilized in the management  of  treatments across multiple cancers. RDA is now being employed in clinical trials for […]

By |November 18th, 2015|Uncategorized|0 Comments

Newsletter Fall 2015

RDA™ Evolves into Platform Technology
While the primary focus of RNA Disruption Assay (RDA) continues to be breast cancer chemotherapy management, it is rapidly evolving into a platform technology that will be utilized in the management  of  treatments across multiple cancers. RDA is now being employed […]

By |October 29th, 2015|Uncategorized|0 Comments

First place for Rna Diagnostics in RESI Innovation Challenge

Rna Diagnostics was awarded first place in the RESI Innovation Challenge held in Boston, Massachusetts on September 16, 2015. The RESI Investor conference included an Innovation Challenge featuring 30 of the most innovative early stage life science companies selected from over 250 biotech, medtech and […]

By |September 21st, 2015|Uncategorized|0 Comments

RNA Disruption Assay (RDA™ ) appears superior to a pCR as a chemotherapy response biomarker

Rna Diagnostics announces the study, Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy, recently published in Breast Cancer Research and Treatment.

Rna Diagnostics is a Canadian cancer diagnostics company developing diagnostic tools to improve chemotherapy management. The company’s first product, RDA, evaluates early in a woman’s […]

By |September 10th, 2015|Uncategorized|0 Comments

NORCAT Innovation Mill client RNA Diagnostics closes round of angel investment

RNA Diagnostics, a Sudbury-based medical diagnostic company, has successfully closed an additional round of angel investment with support of the NORCAT Innovation Mill Angel group.

RNA Diagnostics, with their patented RNA Disruption Assay™ (RDA™), enables clinicians to identify patients who are not responding to chemotherapy early […]

By |July 31st, 2015|Uncategorized|0 Comments

NORCAT’s Innovation Mill and Rna Diagnostics on CTV Northern Ontario News

NORCAT’s Innovation Mill helps accelerate the growth of innovative companies like Rna Diagnostics. View clip

By |January 27th, 2015|Uncategorized|0 Comments

NORCAT’s Innovation Mill and Rna Diagnostics on CTV Northern Ontario News

NORCAT’s Innovation Mill helps accelerate the growth of innovative companies like Rna Diagnostics. View clip

By |January 27th, 2015|Uncategorized|0 Comments

Rna Diagnostics’ RDA™ To Offer Significant Savings to Healthcare Systems

Interactive cost benefit model shows use of RDA in the neoadjuvant setting cost effective for German payers.

Breast cancer stakeholders attended the 34th Annual Meeting of the German Society for Senology conference featuring up-to-date breast cancer diagnostics and therapies. RDA was represented there via Assessment in […]

By |July 2nd, 2014|Uncategorized|0 Comments

New research shows application for Rna Diagnostics’ RDA™ in cancer drug development – Ontario Genomics Institute

The utility of Rna Diagnostics’ RDA™ (Rna Disruption Assay) test in assessing the effect of chemotherapy drugs has been further illustrated in research just published by Toronto biopharma company Armour Therapeutics. The study entitled “Relaxin antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts” was […]

By |May 19th, 2014|Uncategorized|0 Comments

New research shows application for Rna Diagnostics’ RDA™ in cancer drug development – Ontario Genomics Institute

The utility of Rna Diagnostics’ RDA™ (Rna Disruption Assay) test in assessing the effect of chemotherapy drugs has been further illustrated in research just published by Toronto biopharma company Armour Therapeutics. The study entitled “Relaxin antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts” was […]

By |May 19th, 2014|Uncategorized|0 Comments